HAEHaemonetics Corporation
Is it growing?
Growth is fading: earnings down −37% year on year and operating margin narrowing (−5.6 points).
Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +8% a year.
Trailing-twelve-month earnings per share against a year earlier. Growing slower than revenue, so the growth is costing something.
Trailing-twelve-month operating margin, 12.0% now against 17.6% a year earlier.
All from SEC EDGAR, as of Jun 27, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.
Is HAE growing?
Haemonetics Corporation has grown revenue 3.5% a year over three years and 8.4% a year over five, with earnings per share compounding at −7.9%.
Revenue growth, 3-year annual rate · Medical Devices median +12% · growing slowly · compounded from trailing twelve-month revenue
- Revenue growth, 5-year rate
- +8.4%
Revenue growth, 5-year rate · +3.5% over three · growth has slowed since the five-year average
- Earnings per share, 3-year rate
- −7.9%
Earnings per share, 3-year rate · revenue +3.5% · earnings lagged revenue: the growth is costing something
- Years of annual history on file
- 18
Years of annual history on file · FY2009 to FY2026, as filed
Details›
- Revenue FY2022
- $993M
- Revenue FY2023
- $1.17B
- Revenue FY2024
- $1.31B
- Revenue FY2025
- $1.36B
- Revenue FY2026
- $1.33B
Annual income statements as filed with the SEC.